Novo Nordisk A/S (BVMF:N1VO34)

Market Cap	1.08T -49.4%
Revenue (ttm)	267.62B +6.4%
Net Income	88.70B +1.4%
EPS	19.94 +1.8%
Shares Out	n/a
PE Ratio	12.22
Forward PE	13.98
Dividend	0.87 (2.79%)
Ex-Dividend Date	Aug 15, 2025

Volume	93,809
Average Volume	116,338
Open	30.00
Previous Close	28.48
Day's Range	29.90 - 31.15
52-Week Range	28.37 - 67.84
Beta	0.40
RSI	35.34
Earnings Date	Feb 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers pro...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 78,554
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: N1VO34

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK